written on 03.06.2014

Bayer signs €50m deal for Orion's prostate cancer drug


Bayer and Orion will jointly develop the drug, with Bayer contributing a major share of the costs of future development and retaining global commercialization rights. Orion will have the option to co-promote the drug in Europe and will be responsible for…